HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease.

AbstractBACKGROUND AND AIMS:
We aimed to determine the frequency of von Hippel-Lindau disease (vHL) as the underlying cause of retinal hemangioblastoma and to estimate retinal hemangioblastoma incidence and prevalence in a national cohort study.
METHODS:
Through the national patient register and vHL research database, we identified 81 patients diagnosed with a retinal hemangioblastoma in Denmark between 1977 and 2014. Consent was obtained for 54 living and 10 deceased patients with retinal hemangioblastoma. For each participant, we collected medical records and family information. Almost all (63 of 64) participants were or had previously been tested for mutations in the VHL gene.
RESULTS:
Overall, 84% of the participants (54 of the 64) had vHL. Compared with the non-vHL patients, the vHL patients had their first retinal hemangioblastoma at a younger age (22.5 vs 40 years), and were more likely to have an asymptomatic first hemangioblastoma (80% vs 20%). Overall, 76% (41 of 54) of the vHL patients had a family history of vHL, while none of the patients without vHL did. Despite the rarity of the disease, on average more than eight new tumours are diagnosed each year due to multiple tumour development in vHL patients. The estimated prevalence of patients with retinal hemangioblastoma was up to 1 in 73 080 individuals.
CONCLUSION:
In the first national study in which almost all participants were genetically tested, vHL was the underlying cause of retinal hemangioblastoma in 84% of cases; more often than previously reported. We recommend that genetic and clinical vHL screening should be performed in all patients with retinal hemangioblastoma.
AuthorsMarie Louise Mølgaard Binderup, Anne-Sophie Stendell, Michael Galanakis, Hans Ulrik Møller, Jens F Kiilgaard, Marie Luise Bisgaard
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 102 Issue 7 Pg. 942-947 (07 2018) ISSN: 1468-2079 [Electronic] England
PMID28972023 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Chemical References
  • Von Hippel-Lindau Tumor Suppressor Protein
  • VHL protein, human
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Child
  • Cohort Studies
  • Databases, Factual
  • Denmark (epidemiology)
  • Female
  • Germ-Line Mutation
  • Hemangioblastoma (epidemiology)
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Prevalence
  • Registries
  • Retinal Neoplasms (epidemiology)
  • Von Hippel-Lindau Tumor Suppressor Protein (genetics)
  • Young Adult
  • von Hippel-Lindau Disease (epidemiology, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: